MedTrace Logo

Endocrine Disruptors in Saliva Released From Bruxism Splints.

NCT06088238 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2024-03-15

No results posted yet for this study

Summary

The effects of endocrine disruptors (EDs) are well known. Therefore, the aim of this observational study is to analyse saliva samples from volunteers who request a bruxism splint, before, during and after fitting, to find out whether they are assimilated by the body, answering the following questions:

* Do Michigan-type splints release endocrine disruptors or substances of particular concern?
* In what concentration are they present in saliva?

Participants will be asked to take saliva samples at different times over a period of 6 months. This will also be accompanied by the relevant clinical and oral history. A previous in vitro study is required, which is complemented by an in vivo study. The methodology is new in dentistry: super solvents which, combined with liquid chromatography coupled to a mass spectrometer (LC-HRMS), allows a wider range of substances to be detected, in a more ecological and simpler way, as they are not organic solvents derived from petroleum. The splint is chosen because it is an everyday treatment, which is increasingly in demand, especially after the pandemic. It is subdivided into two types, depending on the method of manufacture: injected and printed (more ecofriendly).

Conditions

  • Bruxism

Sponsors & Collaborators

  • Universidad de Córdoba

    collaborator OTHER

  • Universidade da Coruña

    collaborator OTHER

  • Universidad Europea de Madrid

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-20
Primary Completion
2024-09-20
Completion
2024-12-20

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06088238 on ClinicalTrials.gov